PPARA and pancreatitis: Fenofibrate, an FDA approved and commonly prescribed PPARα agonist, demonstrates efficacy in many of these indications, but suffers from limitations such as rapid hydrolysis to its active metabolite, fenofibric acid, which exhibits low receptor affinity, poor selectivity across PPAR subtypes (α, γ, δ), and dose-dependent toxicities (e.g., renal injury, pancreatitis) [9].